Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | RAD52 | P43351 | 1/20 | 0.52 |
| ▸ | HTR3A | P46098 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25811785 | 0.99 | KMT2A (0.69) | KMT2AMEN1MAPTNPSR1CYP1A2 | |
| SCHEMBL25812228 | 0.98 | KMT2A (0.64) | KMT2AMEN1MAPTNPSR1CYP1A2 | |
| SCHEMBL25811723 | 0.93 | RAD52 (0.61) | KMT2AMEN1MAPTNPSR1RAD52 | |
| SCHEMBL25811716 | 0.88 | KMT2A (0.66) | KMT2AMEN1MAPTNPSR1RAD52 | |
| SCHEMBL25811765 | 0.85 | KMT2A (0.71) | KMT2AMEN1MAPTNPSR1CYP1A2 | |
| SCHEMBL25811770 | 0.84 | KMT2A (0.66) | KMT2AMEN1MAPTNPSR1CYP1A2 | |
| SCHEMBL25300551 | 0.82 | KMT2A (0.76) | KMT2AMEN1MAPTNPSR1RAD52 | |
| SCHEMBL25811381 | 0.81 | KMT2A (0.78) | KMT2AMEN1MAPTNPSR1CYP1A2 | |
| SCHEMBL30401813 | 0.80 | RAD52 (0.74) | KMT2AMEN1MAPTNPSR1RAD52 | |
| SCHEMBL25811302 | 0.80 | RAD52 (0.74) | KMT2AMEN1MAPTNPSR1RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218573-A1 | INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | GALYAN BIO INC (US) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218573-A1 | INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | HTT, HYPK, PARK7 | KMT2A 981/4885MEN1 3841/4885MAPT 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.